• SGMD signs agreement to lease five acres of land in Northern California
• Company preparing required documentation to apply for approval for construction of greenhouses, processing building
• Sugarmade to market cannabis as both white-label and branded cannabis products; also likely be distributed through BudCars Cannabis Delivery Service

Sugarmade (OTC: SGMD), a product and branding marketing company investing in operations and technologies with disruptive potential, has signed an agreement to lease five acres of land in Northern California (https://ibn.fm/Sd9Kk). SGMD intends to use the property, which is zoned for cannabis cultivation, to establish and operate a licensed cannabis production business capable of producing as much as 3.6 million grams of high-quality cannabis flower per year.

“We believe we have all of the strategic pieces in place to capitalize on cultivation, with the market currently chronically undersupplied,” said Sugarmade chairman of the board, CEO and CFO Jimmy Chan. “We also have relationships in place, especially through our BudCars investment, to hit the ground running on the branded products side, driving strong margins up and down the chain.”

Sugarmade is leasing the land from LMK Capital LLC and is in the process of obtaining cannabis cultivation licensing for the property. In addition, SGMD is preparing archaeological and biological surveys and assembling architectural and engineering plans, the initial steps necessary for construction of greenhouses and a processing building. The company is working closely with county officials as it follows the outlined processes and prepares to submit appropriate documentation and applications for approval.

The company plans to market the cannabis harvested from the farmland in a variety of ways, including as both white-label and branded cannabis products. Some of the cannabis will also likely be distributed through BudCars Cannabis Delivery Service (BudCars), a rapidly growing California cannabis delivery company, in which Sugarmade owns a 40% stake with the option to acquire an additional 30%.

“We continue to take strategic steps toward broadening our exposure to the growth trend in the cannabis market,” Chan commented (https://ibn.fm/qrgOT). “We see this as a secular growth trend that is still very much in its early innings. And we believe our positioning in California puts us close to the current epicenter of that trend. In addition, we are committed to increasing verticalization of operations as a context for our investment in the BudCars cannabis delivery business. If we are able to finalize the lease, we expect that this could drive a substantial widening of margins on the growing volume of BudCars sales.”

BudCars is a retail business that offers same-day delivery of top-quality cannabis. Customers choose from a variety of products including edibles, flower, pre-rolls, vapes, tinctures and concentrate across dozens of premium brands. Once consumers complete their purchases online, they receive their order the same day via BudCars Cannabis Delivery Service.

Sugarmade Inc. is a product and branding marketing company investing in operations and technologies with disruptive potential. In addition to its financial interest in the BudCars brand, SGMD’s brand portfolio includes CarryOutsupplies.com and SugarRush(TM).

For more information, visit the company’s website at www.Sugarmade.com.

NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SUGAR

• Sanwire Corp. is leveraging technology to consolidate music industry as a highly fragmented marketplace
• Through its subsidiary Intercept Music Inc., the company has developed a single platform offering independent artist distribution, marketing and monetization of music in one place
• This powerful artist-focused platform is transforming music recording space, allowing independent artists to reach and engage millions of fans worldwide

Sanwire Corp. (OTC: SNWR), a Las Vegas, Nevada-based diversified company focused on investing in the entertainment technology space, and its wholly owned subsidiary Intercept Music Inc., has announced the release of version 2.0 of its software platform and website www.InterceptMusic.com.

Founded in 1997, Sanwire Corp. is centered around music and podcast distribution as well as marketing, merchandising, licensing and label services. The company focuses on identifying unique opportunities in entertainment fragmented markets and developing advanced technologies to consolidate distinct services into unified delivery platforms.

Through its wholly owned subsidiary Intercept Music, Sanwire offers a unique combination of artist-focused services. These services are available through the company’s proprietary online platform designed to assist independent artists and bands in promoting their music and distributing it globally through hundreds of digital stores and major streaming platforms, such as Spotify, Amazon Music, Apple Music, Pandora and Google Music. In what SNWR calls  “a marriage of experience and tech,” the platform offers a single solution that blends distribution, marketing and monetization in one place so recording artists can focus on what they are most passionate about — their music.

Intercept Music recently released the latest version of the platform, designed to help recording artists reach audiences in more than 230 countries worldwide and earn income from their music (https://ibn.fm/DUDZL). As a powerful tool that offers customized marketing on all major social media platforms, the upgraded version of the platform enables artists to manage their marketing efforts across all social media channels from a single dashboard. That dashboard provides access to analytics that reveal the effectiveness of the strategy including indicators such as the number of new followers, followers base growth rate, and aggregate revenues’ overview as well as individual revenue streams.

The newly released version also allows artists to identify where their music was streamed and downloaded, and reveal the streaming service employed, helping them better understand their market. The enhanced version also involves scalable features developed to allow a rapid expansion for the company and artists alike. In addition to existing major streaming platforms, the upgraded version introduced more than 20 new digital retailers to assist artistic clients in increasing their revenues.

“Despite the global pandemic, domestic hurricanes and domestic forest fires, we remain focused on helping our clients — independent artists and bands — to achieve their goals by empowering them with seamless productivity tools resulting in an exceptional experience,” said Intercept Music president Tod Turner.

Although present in the entertainment industry for a number of years, where it helped artists earn many awards including more than 100 Grammys, Sanwire Corp. continues to be committed to rapid growth, expanding quickly to generate revenues. As a fast-growing, technology-based entertainment company, Sanwire Corp.’s robust business model is centered around applying technology to integrate multiple services into a single platform of delivery backed by professionals with years of industry experience.

For more information, visit the company’s website at www.SanwireCorporation.com and www.InterceptMusic.com.

NOTE TO INVESTORS: The latest news and updates relating to SNWR are available in the company’s newsroom at https://ibn.fm/SNWR

• Citi experts predict gold could reach $2,100 an ounce this quarter, $2,300 in the next 6 to 12 months
• Precious metal’s consistent performance has resulted in investors looking to reduce risks, maintain purchasing power by buying more gold
• GOH recently entered into agreements to acquire seven advanced gold projects in the Maricunga Gold Belt of Chile

In a detailed explanation of why gold will likely continue its upward trend for at least the foreseeable future, Citi economists conclude that “you would expect gold to perform extremely well” (https://ibn.fm/ZY4Q2). That upward trajectory stands to benefit a wide variety of companies operating in the gold industry, including GoldHaven Resources (CSE: GOH) (OTCQB: ATUMF), a Canada-based company engaged in the business of acquiring and exploring mineral resource properties.

A recent CNBC article, titled “Citi Economists Explain Why Gold Surged Above $2,000, and What It Could Tell Us,” stated that the “spot gold price, which currently stands around $2,058 an ounce, has risen over 4% this week and is set for its ninth week of gains in a row, it’s longest consecutive weekly increase since 2006.” The article goes on to quote Citi experts who said they believed the metal could reach $2,100 an ounce this quarter, and $2,300 in the next 6 to 12 months, with “risks skewed to the upside.”

A core reason behind the precious metal’s steady rise upward, the economists explained, was the “central banks’ monetary easing, which had resulted in negative real yields. This is when the return investors get on bonds is equal to or below the rate of inflation. This has reduced the ‘opportunity cost of holding a zero-coupon asset such as gold.’”

The consistent performance of gold has resulted in investors looking to reduce their risks and maintain the purchasing power of their assets by buying more gold, reported “Forbes” in an article titled “Gold Prices To Surge As Investors To Spend Another $2-3 Trillion, Report Says” (https://ibn.fm/dReCH). Quoting a report by Sprott, a Toronto-based precious metals asset manager, the article noted that “most investors know that gold is a good diversifier of overall risk when held in a portfolio of other assets. Also, over long periods, bullion is said to keep its value in inflation-adjusted terms. Investors are poised to pump an additional $2-3 trillion into the gold market in the wake of the Covid-19 crisis, experts say.”

That is good news for GoldHaven Resources, which recently entered into agreements to acquire seven advanced gold projects in the Maricunga Gold Belt of Chile that hosts over 100 million ounces of gold within the last 10 years. These projects total more than 25,000 hectares (approximately 100 square miles) and include four projects that have been categorized as high priority: the Rio Loa project, the Coya project, the Alicia project and the Roma project. The company has plans to phase in a drilling program commencing in early 2021.

GoldHaven is a Canadian junior exploration company active in the Maricunga Gold Belt of Northern Chile. The Maricunga measures 150 km north-south and 30 km. east-west and is host to discoveries in the last 10 years of 100M oz. gold; 450M oz. silver and 13 billion lbs. copper.

For more information, visit the company’s website at www.GoldHavenResources.com.

NOTE TO INVESTORS: The latest news and updates relating to ATUMF are available in the company’s newsroom at http://ibn.fm/ATUMF

• SRAX has announced acquisition of LD Micro, a leading data company serving small and micro-cap listed company space
• SRAX will pay gross consideration of 1.6 million new SRAX shares along with four $1 million installments
• Following acquisition, LD Micro will be wholly-owned subsidiary of SRAX and will continue to employ Christopher Lahiji, its founder, as president
• Christopher Lahiji has also been named to SRAX Board of Directors

SRAX (NASDAQ: SRAX), a financial technology company focused on unlocking data and insights for publicly traded companies through Sequire, its SaaS platform, announced that it had recently closed the acquisition of LD Micro, a leading data and event company serving the small and micro-cap space (https://ibn.fm/qBBEN). SRAX will pay a total consideration of 1.6 million new Class A SRAX common shares to LD Micro’s shareholders, which will be subject to a 36-month lock-up in addition to four quarterly installments of $1 million, with the first payment made upon the closing of the acquisition.

LD Micro was founded in 2006 with the purpose of providing investors with an independent resource into the listed micro-cap space. What started out as a newsletter highlighting unique companies eventually transformed into several influential events, which have firmly entrenched themselves as must-attend occasions for members of the listed micro-cap universe and institutional investors alike. Separately, LD Micro also launched ldmicro.com, a portal providing exclusive intraday information on the entire sector, including the first pure micro-cap index (LDMi) which covers stocks in North America boasting market capitalizations between $50 million to $300 million.

In early September, LD Micro held its flagship Main Event conference, which attracted over 1,500 delegates and hosted close to 300 innovative companies derived from a variety of sectors, including technology, biotech, pharmaceuticals, and alternative energy among various others. In illustration of the considerable breadth of the company’s flagship conference, the event featured a number of keynote addresses focused around noteworthy updates within the IPO market for North American microcaps.  Discussions centered around the evolution of cryptocurrency as well updates from the Securities & Exchange Commission on recent regulatory developments within the listed microcap equity universe.

Following the acquisition, LD Micro will become a wholly-owned subsidiary of SRAX and will continue to employ Christopher Lahiji, its founder, as president. Mr. Lahiji has also been appointed to the board of directors of SRAX.

A more comprehensive description of the terms and conditions of the transaction is disclosed, and copies of the transaction documents are filed, in the Company’s current report on Form 8-K filed with the Securities Exchange Commission on September 11, 2020, which is available on the Company’s website and at www.SEC.gov.

For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Transformation Capital features SHRG as top performer in the TDSI direct-selling index
• SHRG achieved a staggering 1,070% growth rate compared to levels at end of February
• Industry as a whole has been outperforming market, with positive outlook for full year

Sharing Services Global (OTCQB: SHRG), a diversified holding company specializing in the health and wellness direct-selling industry, was featured in a recent industry report published by investment banking and business development firm Transformation Capital (https://ibn.fm/kwVLW); the report listed SHRG as one of the fastest-growing small-cap companies in the space.

The report looks at the TDSI, or a market capitalization-weighted index of all U.S. publicly traded, direct-selling companies with valuations of more than $25 million. The index started tracking data beginning March 1, 2020, and now stands 56% above the initial end-of-February level, significantly outperforming the DJIA and S&P 500, which gained only 7% during the same period, demonstrating that the industry as a whole is growing much faster than general economy.

The investment bank and business development firm highlights Sharing Services Global as the top performer among all stocks in the index’s tracking set. In fact, SHRG has continued its impressive growth with a gain of 27% during August only, which means that for September, SHRG’s stock price stood at a massive 1,070% above its levels at the end of February.

Transformation Capital estimates that the industry will continue to perform in 2020, leveraging the momentum built since the beginning of the year to drive the industry towards a possible new record-breaking year. “From a broad perspective, we believe that the direct-selling industry, as a whole, is experiencing a renaissance within the domestic market,” said Transformation Capital CEO. “Domestic direct-selling revenues have been flat to slightly down since reaching an all-time high of more than $36 billion in 2016. It is our belief that 2020 sales will reach, and likely exceed, that record figure.”

The investment banking and business development firm see several bullish factors driving robust performances in the direct-selling industry, including the decline in short interest in industry stocks demonstrating that investors are becoming reluctant to take positions against them. As a result, the sentiment of the analysts covering this space is shifting, with a staggering 97% of them having “buy” or “hold” ratings on the stocks from the direct-selling space. Operating in a rapidly growing industry, SHRG offers compelling growth potential supported by its robust business model and strong fundamentals.

The Sharing Services combined platform currently leverages the capabilities and expertise of various companies that market and sell products direct to the consumer through independent contractors. Two of its primary divisions include Elevacity Holdings LLC., the parent of its wholly owned subsidiary, Elevacity U.S. LLC, a health and wellness products company, and Elepreneurs Holdings LLC., the parent of its wholly owned subsidiary, Elepreneurs U.S. LLC, a sales and marketing company based on utilization of independent contractor distributors who sell the Elevacity product line.

For more information, visit the company’s website at www.SHRGInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Kaival Brands’ flagship product, vaping device Bidi(TM) Stick, has rapidly taken dominant position in e-cigarette market
• E-cigarette segment set to grow to market size of $59.3 billion by 2027, CAGR of 19.6% over next seven years
• The Bidi(TM) Stick now available across thousands of retailers in United States, as far afield as Guam
• Kaival Brands recently reported blowout earnings, with quarterly sales surpassing $32 million

Kaival Brands Innovations Group (OTCQB: KAVL), which focuses on growing and incubating innovative and profitable products into mature, dominant brands, is the sole distributor of the Bidi(TM) Stick, an innovative completely-contained disposable nicotine vaping device designed to provide adult smokers with a premium vaping experience. The Bidi(TM) Stick has rapidly taken on a dominant position within the global e-cigarette market – a segment which is projected to grow to a market size of $59.3 billion by 2027, representing a CAGR of 19.6% over the next seven years. With consumers increasingly opting to switch to e-cigarettes amid growing awareness of the advantages of consuming smokeless and ashless nicotine products, brands such as Kaival Brands are well-positioned to make their presence felt in a space where innovation and compliance are essential determinants of success (https://ibn.fm/d8kEm).

Kaival Brands has established a budding reputation for growing and incubating innovative products and developing them into dominating in their respective markets– an approach which the company is now bringing to the rapidly growing vaping sector. As the exclusive distributor of the Bidi Stick, Kaival has sought to create a national distribution network, with the company’s products now stocked across thousands of retail and convenience store locations across the country.

“We are proud to announce that Bidi Sticks can now be found nationally in over 850 retail stores, like Fas Mart and Sprint Mart, owned by GPM Investments LLC in addition to over 2,200 current Circle K convenience stores, and we expect in the coming months for our distribution to expand potentially into thousands more retailers and convenience chains,” said Kaival president and CEO Niraj Patel (https://ibn.fm/Ppj4Z). “Bidi Sticks can also be purchased online for in-person delivery from any goPuff.com facility that has the ability to sell Bidi Sticks legally with proper age-verification gates within that state or municipality.”

Kaival Brands’ ambition is not limited to the United States, having recently begun exports of the Bidi Stick to foreign retailers.

“Internationally, we also recently shipped an initial order valued at approximately $166,000 to Ambros Inc., a company located in Guam that is the exclusive distributor of SC Johnson and Budweiser products to all retailers located in Guam,” Patel continued. “The Bidi(TM) Stick will be the only vaping device offered by Ambros Inc. to their customers and retailers.”

The impressive distribution network for the Bidi(TM) Stick coupled with the product’s innovative design and technological prowess have translated into strong financial results, with Kaival Brands Innovations Group recently releasing its third quarter earnings. Sales for the quarter ending July 31, 2020 totaled approximately $32.4 million, with gross profits of $4.4 million over the three-month period –with the figures being particularly noteworthy given that the company began to generate revenues less than twelve months ago. The company’s management attributed most of the gain to the Bidi Stick’s explosive sales growth.

“We had an extremely busy and fruitful third fiscal quarter,” said Patel. “We experienced a rising demand for our exclusively distributed premium product, the Bidi Stick. We have seen an increase in sales of almost 44% from the previous quarter, with our sales growth occurring mostly organically through smaller distribution channels and wholesalers. Now in the fourth fiscal quarter, we are focused on expanding our distribution into large national retailers and convenience chains.”

With the vaping industry set to enjoy a double-digit growth for the foreseeable future, Kaival Brands is well-positioned to continue benefitting from the growing popularity of its flagship product, the Bidi Stick.

For more information, visit the company’s website at www.KaivalBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom at http://ibn.fm/KAVL

• PACR has strategic licensing agreement with Phenome One, which owns Canada’s largest live genetic cannabis library
• The company’s optimized farming system distinguishes it from other cannabis operations
• Pac Roots Cannabis Corp.’s commitment to superior genetics involves careful selection of cultivation sites

With its slogan proclaiming “the Future of Genetics,” Canadian cannabis company Pac Roots Cannabis (CSE: PACR) clearly places a top priority on producing premium-quality cannabis strains and products. In fact, while some companies may strive to be the largest cannabis grower, Pac Roots Cannabis Corp. maintains that the quality of the product is paramount.

Pac Roots Cannabis Corp. achieves its goal of producing the highest-quality cannabis by relying on superior genetics, following optimized farming systems and growing in carefully selected cultivation sites. The company’s commitment to superior genetics is represented by its strategic licensing agreement with Phenome One, which owns one of Canada’s largest live genetic cannabis libraries. That library includes more than 350 cultivars that have been lab tested and rigorously field-tested over 30 years (https://pacroots.ca/genetics/).

The company’s optimized farming system also distinguishes it from other cannabis operations. These remarkable farming systems are essential in the company’s unerring quest for a quality product. Pac Roots Cannabis Corp. works closely with its selected partners to optimize cultivation through unique, proprietary methods, including the following essential aspects (https://ibn.fm/5ryoU):

• Custom-formulated nutrients
• Systematic planting of young, hardy cultivars, which provides maximum growth and resilience
• Careful weed control achieved through row compaction and mowing
• Complex irrigation systems that deliver nutrients and spring water directly to each plant site

Finally, the third essential piece of Pac Roots Cannabis Corp.’s commitment to superior genetics involves its careful selection of cultivation sites located in some of the best outdoor growing climates in Canada, including the South Okanagan Valley and the Fraser Valley Regional District.

The company’s Rock Creek Farms site, a 100-acre, premium-hemp joint venture, is nestled in the South Okanagan Valley in British Columbia, an area that has been called both the Golden Mile and the Napa Valley of the North. The company has also announced the closing of a share purchase agreement for 250 pristine acres in the Fraser Valley Regional District (“FVRD”) of British Columbia, one of the most productive and actively farmed areas in Canada (https://ibn.fm/j5u8R). This lush area features high-quality soil, a favorable climate, and an ample water supply.

“The addition of such a substantial package of land to our portfolio is a major step for PacRoots,” said PACR President and CEO Patrick Elliot. “We are pleased to have the opportunity to add significant acreage with an acquisitional cost base of $9,600 per acre. This land has no zoning restrictions and is not situated within the Agricultural land reserve, which provides for infinite development possibilities.”

Pac Roots Cannabis Corp. began operations in 2012 with initial activities directed toward exploration and development of mineral properties in Canada. The company’s mission has evolved through time, and today, Pac Roots Cannabis Corp. is focused on cannabis and hemp cultivation, leveraging high-end genetics and specialized cultivars to produce top-quality products. Preserving the excellence of its elite strains while introducing the highest quality of new strains to the public is the company’s passion. Genetic variation and stability is the foundation that drives the decision-making for Pac Roots Cannabis Corp.’s business.

For more information, visit the company’s website at www.PacRoots.ca.

NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• MVES engaged services of Digital Talent Studio Inc., social media mogul Brian Breach of Sikey Corp. to promote The Movie Studio App
• The Movie Studio App leverages both advertiser-based and subscription models
• Social media models, influencers expected to promote app to hundreds of thousands of followers
• MVES’s two key verticals include open architecture for original content plus an over-the-top platform that pulls additional content through revenue sharing agreements

In a bold move to boost the promotion of The Movie Studio App, The Movie Studio Inc. (OTC: MVES), a vertically integrated motion picture production and distribution company, has engaged Digital Talent Studio Inc. and social media mogul Brian Breach of Sikey Corp. for services that include social media branding, influencer engagement and advertising on key social media platforms. Currently offered as a beta version in the Google Play Store and the Apple App Store, the app is expected to be replaced with the full version once the official launch takes place.

Designed to be a recurring revenue model, MVES’s unique video on demand (“VOD”) business goes beyond traditional feature film distribution pathways by offering innovative ways to distribute content and participate in the motion picture industry. Besides targeting relevant demographics through social media, high-profile influencers will be engaged in a revenue-sharing agreement that includes opportunities to audition in the company’s in-production “Moviesodes”.

“We are excited about engaging Digital Talent Studio Inc. and Sikey Corp. and believe they intrinsically understand the proposed app and our OTT platform architecture,” said MVES President and CEO Gordon Scott Venters (https://ibn.fm/CUKBD). “Upon completion of the app and subsequent marketing aligned with our brand, we are confident they can help us create a significant user subscription base.”

The Movie Studio app will employ a split-screen graphical interface that incorporates both advertiser video on demand (“AVOD”) and subscription-based video on demand (“SVOD”) components. Besides allowing users to watch ad-free for only $2.99/month, the SVOD component will also allow subscribers to participate in the “Be in Our Movies!” portion of the app, allowing them to audition for roles in upcoming films.

“Taking on The Movie Studio’s social media so they can reach their full potential and expand their online presence and the launch of their app could disrupt the entire independent movie industry, and I look forward to helping make that happen,” said Sikey President Brian Breach.

MVES’s two key verticals include an open architecture for the addition of motion picture content to its film library along with an over-the-top (“OTT”) platform that seeks to pull additional motion picture content into the app that leverages revenue share agreements with motion picture producers, distributors and content providers. Following the completion of the app, the initial marketing campaign will be put into play to target millennials and other demographics through high-profile influencers on top social networks like Facebook and Instagram.

“This partnership could take our models and social media influencers to the next level, launching their movie careers so they can be in films,” said Digital Talent Studio president Kevin Doyle.

“Similarly, we may provide the ultimate grassroots marketing campaign for The Movie Studio’s content delivery app and each of their films,” he continued. “Our influencers could announce their roles directly to their hundreds of thousands of followers, creating an instant demand for each movie and the SVOD component of the platform. Reciprocally, each movie can become an opportunity for our influencers to grow their follower bases and a chance to become viral stars.”

Formerly known as Destination Television, Inc., The Movie Studio Inc. acquires, develops, produces and distributes independent motion picture content for worldwide consumption in theatrical, video on demand, foreign sales, and on various media devices. With an aim to disrupt traditional media content delivery systems with its digital distribution model, MVES is well-positioned to become a unique brand within the VOD industry.

For more information, visit the company’s website at www.TheMovieStudio.com.

NOTE TO INVESTORS: The latest news and updates relating to MVES are available in the company’s newsroom at http://ibn.fm/MVES

• Mullen Technologies begins built-out of pilot facility, accepting orders for MX-05 SUV.
• Facility slated for April 2021 completion; first MX-05 SUVs rolling off production line by Q2 2022.
• In August, Net Element, Mullen Technologies announced execution of definitive agreement to merge.

The announcement by Mullen Technologies Inc. that it has begun to build out its pilot manufacturing facility and take pre-orders for its M05 fully electric SUV bodes well for Net Element (NASDAQ: NETE). Earlier this year, Net Element, a global financial technology and value-added solutions group, and Mullen Technologies announced a merger agreement—so good news for Mullen means good news for Net Element.

“We are excited to begin the build-out of our pilot facility and pre-sales of our MX-05 SUV in October,” said Mullen Technologies chairman and CEO David Michery. “We plan on completing the build-out by April 2021 and to begin assembly of certification prototypes by July 2021. These vehicles will be used for homologation, which is expected to take 16 months and be completed by May of 2022, at which time we expect to begin delivering the first vehicles to the public.”

On Oct. 1, Mullen began work to turn its Monrovia, California-based, high-voltage battery R&D center into a state-of-the-art pilot facility where its line of fully electric SUVs will be manufactured. Plans call for the facility to be completed by April 2021, with the first MX-05 SUVs rolling off the production line to be delivered to customers by second quarter 2022.

Mullen Technologies anticipates its remodeled manufacturing facility will produce up to 1,000 MX-05 EVs per year; the facility will also manufacture all other upcoming models, including the MX-07 and MX-03. The factory will be renovated to include general assembly and battery assembly capabilities; the structure will also house R&D and serve as a warehouse.

Also on Oct. 1, Mullen will begin accepting preorders for its MX-05 model; starting base price for the innovative vehicle starts at $55,000. In addition, the company is also taking preorders for its Dragonfly K50, a limited-production super sports car being imported under Independent Commercial Importers. Information about both vehicles, as well as how to reserve the EVs, can be found on www.MullenUSA.com or at any Mullen retail location.

In August, Net Element announced the execution of a definitive agreement to merge with privately held Mullen Technologies Inc., in a stock-for-stock reverse merger in which Mullen’s stockholders will receive a majority of the outstanding stock in the post-merger company. The completion of the merger is subject to shareholder and NASDAQ approval, as well as other conditions referenced in the merger agreement.

Net Element Inc. is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the United States and selected emerging markets.

For more information, visit the company’s website at www.NetElement.com.

NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE

• Processa Pharmaceuticals aims to develop products where existing clinical evidence of efficacy already exists in the targeted unmet medical need condition with the drug itself or a drug with very similar pharmacology
• The Processa process focuses on the advancement of drugs that are ready for clinical development or have minimal pre-IND enabling studies to complete
• Processa’s current development pipeline features multiple clinical drug candidates, given the recent acquisitions of three additional development-focused licensing agreement since June 2020
• In total, the company’s combined scientific, development and regulatory experience has resulted in more than 30 drug approvals by the U.S. Food and Drug Administration

Processa Pharmaceuticals (NASDAQ: PCSA) aims to develop products where existing clinical evidence of efficacy already exists in unmet medical need conditions. In support of this goal, the company has assembled an unparalleled management team, board of directors and product development team featuring experts in developing drug products, from IND-enabling studies to NDA submission. In total, the team’s combined scientific, development and regulatory experience has resulted in more than 30 drug approvals by the U.S. Food and Drug Administration (“FDA”) and more than 100 meetings with the FDA while working on more than 50 drug development programs, including drug products targeted to orphan disease and unmet medical need conditions.

Headquartered in Hanover, Maryland, Processa has built a pipeline of drugs which already have some proof-of-concept clinical data supporting clinical use in their selected indications.

Development Pipeline

The Processa process focuses on the advancement of drugs that are ready for clinical development or have minimal pre-IND enabling studies to complete. More specifically, Processa:

1. Acquires drugs that already have some clinical data to support the targeted treatment – whether it be the drug itself, an analog of the drug or a drug with similar pharmacological targets;
2. Navigates through the FDA, collaborating with the reviewers to define a complete development program; and
3. Develops each drug over the course of 2-5 years, out-licensing the drug either just prior to pivotal study after Phase 2b or after the completion of the pivotal study.

Processa’s current development pipeline features multiple drug candidates, including PCS499 and PCS100. The company has also announced three additional licensing agreements since June 2020, further bolstering its clinical efforts. Each drug is briefly described below.

PCS6422

On August 27, 2020, Processa announced its entry into a contingent precedent exclusive licensing agreement with Elion Oncology Inc. to develop, manufacture and commercialize eniluracil (PCS6422) globally. PCS6422 is an oral drug to be administered with fluoropyrimidine cancer drugs (e.g., capecitabine, 5-FU) to decrease the breakdown of the cancer drug to inactive metabolites or metabolites that are known to cause unwanted side effects and to increase the anti-cancer related metabolites.

An IND for a Phase 1B study was cleared by the FDA in May 2020. The study will evaluate the safety and tolerability of several dose combinations of PCS6422 and capecitabine in advanced GI tumor patients. Processa intends to enroll the first patient in 1H2021, obtain interim results, and have a final report completed in 2H2022.

“Having worked on 5-FU and other cancer agents in the past, adding PCS6422 to our pipeline and expanding our involvement in oncology was an easy decision given the significant impact that PCS6422 may have on improving the efficacy and safety of capecitabine or other fluoropyrimidines,” CEO Dr. David Young said of the agreement.

PCS499

PCS499 as a potential treatment for necrobiosis lipoidica (“NL”) was first presented to the FDA in a pre-IND meeting in 2018. In 2019, it was the subject of an IND submission and a promising Phase 2 safety study. On March 30, 2020, Processa announced a successful meeting with the FDA regarding the design and execution of the next clinical study to evaluate the ability of PCS499 to completely close ulcers in patients with NL.

“We are pleased with the outcome of the FDA meeting and the feedback we received from the FDA. We believe that the results from our completed Phase 2 trial in NL patients, especially those with more severe ulcerated forms of NL, are encouraging and we appreciate the guidance provided by the FDA regarding our next clinical trial and the requirements to support our NDA submission,” Dr. David Young, CEO of Processa, stated in the news release.

NL is a chronic, disfiguring condition affecting the skin and tissue under the skin, typically on the lower extremities, with no currently FDA-approved treatments. More severe complications can occur, such as deep tissue infections and osteonecrosis, threatening the life of the limb. Approximately 22,500 – 55,500 people in the United States and more than 150,000 – 400,000 people worldwide are affected by the ulcerated form of NL.

YH12852

On August 20, 2020, Processa announced its entry into an agreement with Yuhan Corporation, a South Korean firm, to license YH12852, a small molecule drug in development for the treatment of functional gastrointestinal (“GI”) disorders. Under the terms of the agreement, Processa will acquire the rights to a portfolio of patents with an exclusive license to develop, manufacture and commercialize YH12852 globally, excluding South Korea.

YH12852 is a novel, potent and highly selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. Other 5-HT receptor agonists with less 5-HT4 selectivity have been shown to successfully treat GI mobility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome, functional dyspepsia and gastroparesis. The less selective 5-HT4 agonists, such as cisapride, have been removed from the market because of the cardiovascular side effects associated with the drugs binding to other receptors, especially 5-HT receptors other than 5-HT4.

CEO Dr. David Young called the agreement “further evidence of Processa’s commitment to seek out novel treatments for unmet medical conditions.” Processa intends to meet with the FDA in early 2021 to further define the clinical development program. In 2021, Processa expects to initiate a Phase 2 trial in a functional GI motility-related disorder that that needs better therapeutic options, such as postoperative ileus and opioid-induced constipation.

ATT-11T

On June 1, 2020, Processa announced its entry into a licensing agreement with Aposense Ltd. for the patent rights and know-how to develop and commercialize ATT-11T, a next generation irinotecan cancer drug. In the release, CEO Dr. David Young noted that the licensing deal fit with Processa’s strategy to “continue to bring innovative products to patients with an unmet medical need condition.”

ATT-11T is a novel lipophilic anti-cancer pro-drug that is being developed for the treatment of the same solid tumors as prescribed for irinotecan. This pro-drug is a conjugate of a specific proprietary Aposense molecule connected to SN-38, the active metabolite of irinotecan. The proprietary Aposense molecule on ATT-11T allows ATT-11T to bind to cell membranes to form an inactive pro-drug depot on the cell, with SN-38 preferentially accumulating in the membrane of tumors cells and the tumor core. This unique characteristic is expected to make the therapeutic window of ATT-11T wider than irinotecan, such that the anti-tumor effect of ATT-11T will occur at a much lower dose than irinotecan with a milder adverse effect profile than irinotecan. The wider therapeutic window will likely lead to more patients responding with less side effects when on ATT-11T compared to irinotecan.

The ATT-11T licensing agreement is conditioned upon Processa’s closing of a satisfactory financing round and the listing of the company’s shares on the Nasdaq or NYSE, among other conditions.

PCS100

On September 3, 2020, Processa announced its entry into an exclusive worldwide license agreement with Akashi Therapeutics to develop and commercialization Akashi’s lead drug, HT-100. Rebranded PCS100, the candidate is an anti-fibrotic, anti-inflammatory drug demonstrated to have some clinical anti-fibrotic effect in children. Processa intends to develop PCS100 first in rare adult fibrotic related diseases such as focal segmental glomerulosclerosis (“FSGS”), idiopathic pulmonary fibrosis (“IPF”) or Scleroderma, where there are still few therapeutic options.

Management Team

David Young, Pharm.D., Ph.D. is the CEO and founder of Processa. He has over 30 years of pharmaceutical research, drug development and corporate experience. Young has served in leadership roles with a number of pharmaceutical firms throughout his career, including serving as founder and CEO of Promet Therapeutics LLC since 2015 and as Chief Scientific Officer of Questcor Pharmaceuticals from 2009 to 2014. At Questcor, he was responsible for working with the FDA on modernizing the Acthar Gel label and for obtaining FDA approval in infantile spasms. In total, Young has met with the FDA more than 100 times on more than 50 drug products and has been a key team member on more than 30 NDA/supplemental NDA approvals.

Sian Bigora, Pharm.D., is Processa’s Chief Development Officer and founder. She has over 20 years of pharmaceutical research, regulatory strategy and drug development experience, working closely with Young. Prior to joining Processa, Bigora served as Co-Founder, Director and Chief Development Officer at Promet Therapeutics LLC and as Vice President of Regulatory Affairs at Questcor Pharmaceuticals from 2009 to 2015, where she led efforts to modernize the Acthar Gel label and obtain FDA approval in infantile spasms – events which were of material importance to Questcor’s subsequent success.

Patrick Lin is Chief Business & Strategy Officer and founder of Processa. He has over 20 years of financing and investing experience in the biopharma sector. Prior to joining Processa, Lin served as Co-Founder and Chairman of Promet Therapeutics LLC. He is also founder and managing partner of Primarius Capital, a family office that manages public and private investments focused on small capitalization companies.

James Stanker has served as CFO of Processa since 2018. He has over 30 years of financial and executive leadership experience in the areas of accounting principles and audit standards, regulatory reporting, and fiscal management and strategy. He served in a financial leadership role as an audit partner at Grant Thornton from February 2000 until his retirement in August 2016, where he was responsible for managing audit quality in the Atlantic Coast market territory.

Wendy Guy is the Chief Administrative Officer and founder of Processa. She has more than two decades of experience in business operations, having worked closely with Young over the last 18 years in corporate management and operations, HR and finance. Prior to joining Processa, she was Co-Founder, Director and Chief Administrative Officer of Promet Therapeutics LLC and Senior Manager, Business Operation over the Maryland office for Questcor Pharmaceuticals.

For more information, visit the company’s website at www.ProcessaPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA